IMMUNIC, INC. Files 8-K Report

TL;DR

IMMUNIC, INC. dropped an 8-K on May 8th covering financials and other key events.

AI Summary

On May 8, 2024, IMMUNIC, INC. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of operations and financial condition, as well as other events and financial statements. IMMUNIC, INC. is incorporated in Delaware and headquartered in New York.

Why It Matters

This 8-K filing provides crucial updates on IMMUNIC, INC.'s financial health and operational activities, which are important for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings can contain a wide range of information, from routine updates to significant events, making the risk level dependent on the specific details within the report.

Key Players & Entities

• IMMUNIC, INC. (company) — Registrant
• May 8, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• New York, NY (location) — Principal executive offices address
• 56-2358443 (identifier) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In

Filing Documents

• e663589_8k-immunic.htm (8-K) — 27KB
• e663589_ex99-1.htm (EX-99.1) — 64KB
• e663589_ex99-2.htm (EX-99.2) — 12KB
• image_001.jpg (GRAPHIC) — 4KB
• slide1.jpg (GRAPHIC) — 279KB
• slide2.jpg (GRAPHIC) — 330KB
• slide3.jpg (GRAPHIC) — 73KB
• slide4.jpg (GRAPHIC) — 47KB
• slide5.jpg (GRAPHIC) — 227KB
• slide6.jpg (GRAPHIC) — 220KB
• slide7.jpg (GRAPHIC) — 251KB
• slide8.jpg (GRAPHIC) — 199KB
• slide9.jpg (GRAPHIC) — 196KB
• slide10.jpg (GRAPHIC) — 42KB
• slide11.jpg (GRAPHIC) — 181KB
• slide12.jpg (GRAPHIC) — 42KB
• slide13.jpg (GRAPHIC) — 156KB
• slide14.jpg (GRAPHIC) — 36KB
• slide15.jpg (GRAPHIC) — 40KB
• slide16.jpg (GRAPHIC) — 118KB
• slide17.jpg (GRAPHIC) — 121KB
• 0001193805-24-000605.txt ( ) — 3816KB
• imux-20240508.xsd (EX-101.SCH) — 3KB
• imux-20240508_lab.xml (EX-101.LAB) — 33KB
• imux-20240508_pre.xml (EX-101.PRE) — 22KB
• e663589_8k-immunic_htm.xml (XML) — 4KB

02. Results of Operations and Financial

Item 2.02. Results of Operations and Financial Condition On May 8, 2024, Immunic, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update (the "Press Release"). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

01. Other Events

Item 8.01. Other Events On May 8, 2024, the Company posted an updated presentation (the "Presentation") on its website. A copy of the Presentation is filed herewith as Exhibit 99.2 and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K, the Press Release and the Presentation are "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K, the Press Release and the Presentation regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company and further updates with respect thereto; the development and commercial potential of any product candidates of the Company; and the Company's expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the for

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits Exhibit Description 99.1 Press Release, dated May 8, 2024. 99.2 Presentation, dated May 8, 2024. 104 Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: May 8, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR